Ann: Exopharm Shareholder Update - Revenue Focus in 2021, page-148

As an example from a Nov 2022 release:

Discussions between BIA and Exopharm have arrived at a Material Transfer Agreement and
associated collaborative program. Over the next few months BIA and Exopharm will test the
addition of LEAP ligand chemistry to the existing BIA CIM monolithic columns. The
expectation is that the addition of LEAP ligands to the CIM will improve specificity and purity
of the purified exosome product over BIA CIM ion exchange columns. BIA will also test
different immobilisation densities of the LEAP ligands to seek an optimal density for high
throughput industrial use.